Clinical trials: Untreated
Lymphoma
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as epratuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00301821
- Testing
- epratuzumab, rituximab, cyclophosphamide
- Where
- 162 sites in United States
- Volunteers
- 107 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hodgkin Lymphoma
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
The purpose of the phase Ib of the study is to identify the maximum tolerated dose (MTD) of Brentuximab Vedotin (BV) in combination with EPEM and to assess the toxicity of the combination of BV with EPEM.
- Trial name
- NCT03576378
- Testing
- BrentuximabVedotin (BV)
- Where
- 15 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
AML (Acute Myeloid Leukemia)
VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
This is a multicenter, prospective, single-arm clinical study designed to evaluate the efficacy and safety of the VA-CIG regimen (venetoclax combined with azacitidine, idarubicin, low-dose cytarabine and granulocyte…
- Trial name
- NCT07514832
- Testing
- Venetoclax, Azacitidine, Cytarabine, Idarubicin, G-CSF
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing 302 Hospital
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
The purpose of this study is to determine the safety of lenalidomide (revlimid) in combination with fludarabine and rituximab and to determine the highest dose of lenalidomide that can safely be given in that combination.
- Trial name
- NCT00543114
- Testing
- Lenalidomide, Fludarabine, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Mucositis
Randomized Study of Beet Root in Locally Advanced Squamous Cell Cancer of the Head and Neck
The objective of the current proposal is to determine if concentrated beet root could improve medical treatment compliance as defined by completion of radiotherapy and 3 cycles of chemoradiation without dose reduction, preserve…
- Trial name
- NCT02058849
- Testing
- Beetroot
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- David Travis Thomas
Prostatic Adenocarcinoma
An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma
Although surgical or medical castration (i.e., androgen-deprivation therapy, ADT) is considered standard treatment in metastatic castration-naïve PC (mCNPC) patients, current guidelines have established the addition docetaxel or…
- Trial name
- NCT06015321
- Testing
- Enzalutamide
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Samsung Medical Center
Follicular Lymphoma (FL)
Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
Follicular lymphoma (FL) remains an incurable indolent B-cell lymphoma for many patients, and although rituximab-based chemoimmunotherapy can achieve high initial response rates, a substantial proportion of patients experience…
- Trial name
- FLOURISH (NCT07550855)
- Testing
- Sotoclax in combination with zanubrutinib and rituximab regimen
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-sen University
Lymphoma
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00004112
- Testing
- rituximab, CHOP regimen, cyclophosphamide
- Where
- 2 sites in United States
- Sponsor
- University of Nebraska
Peripheral T-cell Lymphoma
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
The purpose of this study is to determine the efficacy and the safety profile and toxicity of a combination of Velcade™ (bortezomib) with a standard chemotherapy regimen (ACVBP [doxorubicin, cyclophosphamide, vindesine…
- Trial name
- NCT00136565
- Testing
- Velcade, Doxorubicin, Prednisone
- Where
- 5 sites in Belgium, France
- Volunteers
- 60 people
- Sponsor
- Lymphoma Study Association
Chronic Lymphocytic Leukemia
Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
To compare the clinical efficacy and safety of bendamustine hydrochloride versus chlorambucil for initial treatment of chronic lymphocytic leukemia
- Trial name
- NCT01109264
- Testing
- Bendamustine hydrochloride injection, Chlorambucil
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
To compare the efficacy and safety of ceritinib with standard first-line chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with stage IIIB (not candidates for definitive multimodality therapy) or stage IV…
- Trial name
- NCT01828099
- Testing
- Ceritinib, Pemetrexed, Cisplatin
- Where
- 167 sites in Argentina, Australia and 27 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelodysplastic Syndromes
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
RATIONALE: Combinations of biological substances in DT388IL3 fusion protein may be able to carry cancer killing substances directly to the cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT00397579
- Testing
- DT388IL3
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Hepatitis B
Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatitis B Patients
The World Health Organization (WHO) has set a target to eliminate viral hepatitis by 2030, aiming for a 90% diagnosis rate and an 80% treatment rate for chronic hepatitis B (CHB).
- Trial name
- Union-FAST (NCT07520123)
- Testing
- Agent Intelligence education
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Neoplasms, Diarrhea
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
The study will combine a new investigational drug with standard anti-cancer drugs for the treatment of advanced colorectal cancer.
- Trial name
- NCT00040391
- Testing
- Investigational drug, Irinotecan, 5-fluorouracil
- Where
- 28 sites in United States
- Sponsor
- Celgene Corporation
Leukemia, B-cell Leukemia
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients.
- Conditions
- Leukemia, B-cell Leukemia, Chronic Leukemia, Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT00230282
- Testing
- Alemtuzumab, Fludarabine, Cytoxan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Steven E. Coutre
Leukemia, Myeloid, Acute
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML…
- Trial name
- BRIGHT AML1019 (NCT03416179)
- Testing
- glasdegib, daunorubicin + cytarabine, azacitidine
- Where
- 149 sites in United States, Australia and 20 more
- Volunteers
- 730 people
- Sponsor
- Pfizer
Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies how well giving ofatumumab together with pentostatin and cyclophosphamide works in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma
- Trial name
- NCT01024010
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Ofatumumab
- Where
- 4 sites in United States
- Volunteers
- 82 people
- Sponsor
- Mayo Clinic
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Carcinoma, Non-Small-Cell Lung
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study.
- Trial name
- NCT04585815
- Testing
- Sasanlimab Prefilled syringe, Encorafenib, Binimetinib
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in…
- Trial name
- NCT05775289
- Testing
- Tobemstomig, Pembrolizumab, Paclitaxel
- Where
- 50 sites in United States, Australia and 9 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.